AbbVie Inc., ABBV is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, AbbVie Inc., ABBV has a market cap of 105212.55. Since its IPO date on the 1/2/2013, AbbVie Inc., ABBV performance year to date is 15.65%. Today AbbVie Inc., ABBV has gained -0.26%, with a current price of 66.4.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 70.50%. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at *TBA, with return on investment at 16.90%.
In terms of debt levels and profit levels, AbbVie Inc., ABBV is seeing a long-term debt/equity of *TBA. While Total debt/equity is *TBA. With a profit margin of *TBA, this is combined with a gross margin of 79.80%, and operating margin of 36.40%. AbbVie Inc. ability to meet debt levels, with a current ratio of *TBA, while the quick ratio is *TBA.
For the last year AbbVie Inc., ABBV has seen a EPS growth of 185.20%. A performance for the year of -1.15%. The 52-week high is -2.56%, and the 52-week low is 50.36%. The average volume for AbbVie Inc., ABBV is 1849651.
With a target price of 70.17, can AbbVie Inc., ABBV reach this target? Looking at the value indicators of AbbVie Inc., ABBV. AbbVie Inc. has a P/E of 19.94 and a forward P/E of 11.86. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.24. AbbVie Inc. also has a P/S and a P/B of 4.42 and 23.19 respectively. For P/cash, AbbVie Inc. has a value of *TBA, while it is *TBA for P/free cash flow.
At the current price of 66.4, AbbVie Inc. has a dividend yield of 3.42%. We see a return on equity of *TBA.
Looking more long-term AbbVie Inc., is projected to get an EPS growth for the next five years of 16.03%. In the short-term an EPS growth of 18.10% in the next year is forecasted. This is after a EPS growth of 185.20% for this year and for the last five years a 3.50% growth has been seen.